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Stress Imaging 5 Years After Percutaneous
Coronary Intervention
The Prospective Long-Term Observational BASKET (Basel Stent
Kosteneffektivitäts Trial) LATE IMAGING Study
Michael J. Zellweger, MD,* Gregor Fahrni, MD,* Myriam Ritter, MD,*
Raban V. Jeger, MD,* Damian Wild, MD,y Peter Buser, MD,* Christoph Kaiser, MD,*
Stefan Osswald, MD,* Matthias E. Pﬁsterer, MD,* for the BASKET Investigators
Basel, SwitzerlandObjective This study sought to evaluate the prognostic value of routine stress myocardial perfusion
scintigraphy (MPS) 5 years after percutaneous coronary intervention (PCI).
Background Current appropriate use criteria deﬁne routine cardiac stress imaging <2 years after PCI
as inappropriate and >2 years as uncertain in asymptomatic patients.
Methods All 339 of 683 BASKET (Basel Stent Kosteneffektivitäts Trial) 5-year survivors (55%)
consenting to undergo protocol-mandated MPS and subsequent evaluation irrespective of symptoms
were followed for major adverse cardiac events (MACE) (cardiac death, myocardial infarction [MI], or
revascularization). For MPS, summed perfusion scores were calculated and perfusion defects were
related to treated-vessel or remote myocardial areas.
Results Patients were 72  10 years of age, 18% were female, and 90% were free of angina. MPS
ﬁndings were abnormal in 205 of 339 patients (60%) with complete follow-up. During 3.7  0.3 years,
there were 7 cardiac deaths, 18 MIs, and 47 revascularizations, resulting in a MACE rate of 4.4% and a
cardiac mortality rate of 0.6% per year. Patients with abnormal MPS ﬁndings had higher hazard ratios
(HR) for MACE (HR: 1.95; 95% conﬁdence interval [CI]: 1.06 to 3.59; p ¼ 0.032), and cardiac death/MI
(HR: 2.50; 95% CI: 0.93 to 6.69; p ¼ 0.066) than patients with normal MPS ﬁnding. MACE rates were
similar in patients with symptomatic and silent ischemia (p ¼ 0.61) but higher than in patients with
normal MPS ﬁndings (p < 0.05 for both comparisons). MACE rates were independently predicted by
remote ischemia but not by treated-vessel ischemia or scar.
Conclusions Abnormal MPS ﬁndings 5 years after PCI are frequent irrespective of symptoms. The
predictive power of abnormal MPS lies more in the detection of persistent or progressing coronary
artery disease in remote vessel areas than in the diagnosis of late intervention-related problems in
treated vessels. (J Am Coll Cardiol Intv 2014;7:615–21) ª 2014 by the American College of Cardiology
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616Coronary artery disease (CAD) remains a progressive disease
after successful percutaneous coronary intervention (PCI)
and stent implantation, as recently demonstrated 3 to 5 years
after the PCI (1,2). If progression or problems related to the
previous PCIs lead to recurrent symptoms, then stress im-
aging is recommended according to European and U.S.
guidelines (3,4). Relevant ischemia should then trigger the
performance of coronary angiography and, if possible and
feasible, repeat revascularization. Early after the intervention
(i.e., up to 6 months), positive ﬁndings on single-photon
emission computed tomography myocardial perfusion scin-
tigraphy (MPS) have been shown to predict future events
(5,6). However, routine stress testing (i.e., testing also in
patients without recurrent symptoms) is not advised (7,8),
except for special high-risk patient groups (9). Therefore,
in currently valid guidelines for appropriate use of stress
imaging after PCI, routine stress imaging >2 years after the
intervention has been termed uncertain in asymptomaticAbbreviations
and Acronyms
CAD = coronary artery
disease
CI = conﬁdence interval
HR = hazard ratio
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
MPS = myocardial perfusion
scintigraphy
PCI = percutaneous coronary
intervention
SDS = summed difference
scorepatients on the basis of a lack of
corresponding data (10,11). On
the other hand, a U.S. Food and
Drug Administration expert panel
recommended 5-year outcome
studies for drug-eluting stent safety
(12), but up to that point in time,
progression or new development of
CAD may become as relevant as
very late stent-related problems,
as recently shown (1,2). Still, the
prognostic relevance of such a very
late assessment is unknown.
It was, therefore, the aim of
the present prospective BASKET
(Basel Stent Kosteneffektivitäts
Trial) LATE IMAGING studyto deﬁne the prognostic value of stress MPS 5 years after
successful PCI in a large, well-characterized all-comer PCI
population, irrespective of symptoms, to predict future cardiac
events.
Methods
Patients. All 683 consecutive patients surviving to 5 years
after successful stent implantation of the original BASKET
population were invited to undergo a stress MPS study.
Initially, the BASKET included 826 consecutive patients
in need of PCI and stenting between May 5, 2003 and May
31, 2004, at the University Hospital of Basel, Switzerland,
and randomized them in a 2:1 fashion to drug-eluting versus
bare-metal stents (13). Figure 1 shows that the present study
population consisted of 372 patients (55% of all 683 possibly
available patients or 45% of the entire initial BASKET
population). Of these, 5 patients withdrew consent and 28
were lost during the 3.7  1.3-year follow-up, leaving339 patients (91% of the study population) with complete
outcome data, forming the present prognostic study patient
population.
Stress myocardial perfusion imaging. Stress MPS studies
were performed following a standard protocol and read by
specialists in nuclear cardiology independent of this study
as previously described (1,6). In short, a rest-stress dual-
isotope (thallium-201/technetium-99m sestamibi) protocol
with exercise or pharmacological (adenosine) stress and
electrocardiographic monitoring was used after withdrawal
of antianginal drugs if possible. Images were scored using a
17-segment model with a 5-point scale of 0 (normal) to 4
(no uptake). Summed stress, rest, and difference scores were
calculated. At the time of this MPS study, all patients un-
derwent a clinical visit as the baseline for the present pro-
spective study.
Follow-up. At 3 to 4 years after the 5-year MPS study, all
patients were contacted to answer a dedicated questionnaire
asking about cardiac events, speciﬁcally cardiac death,
myocardial infarction (MI), and repeat revascularization as
well as current symptoms and medications between the
5-year MPS study and the ﬁnal follow-up. If patients could
not be reached or speciﬁc data were missing, relatives and/or
private physicians were contacted to verify survival status
and, if applicable, to assess the cause of death. In addition,
hospital charts were collected for patients hospitalized dur-
ing follow-up and private physicians’ charts were consulted
to verify endpoints.
All patients were asked to provide (new) written informed
consent for the present study and for the use of their data.
The study protocol for this study was approved by the
Ethical Committee of the 2 states of Basel.
Deﬁnitions. The primary endpoint of this prospective
BASKET LATE IMAGING study was major adverse
cardiac events (MACE) (i.e., cardiac death, nonfatal MI,
and repeat revascularization) during follow-up in relation
to MPS ﬁndings (normal or abnormal MPS ﬁndings in the
5-year MPS study). Cardiac deaths, documented MIs ac-
cording to standard deﬁnitions used in BASKET (13), and
all repeat revascularization procedures (PCI and coronary
artery bypass graft surgery) during follow-up were consid-
ered. All revascularizations were counted as endpoints
because revascularization beyond 60 days after testing
generally is considered to be a new event not triggered
by test results and because 7 of 8 early revascularizations
(<60 days) in the current study were performed for an acute
coronary syndrome (n ¼ 1) or extensive ischemia (mean
summed difference score [SDS] was 7.6) with prognostic
relevance (14–16). Secondary endpoints were individual
components of the primary endpoint each separately and
the combined endpoint of cardiac death/MI. Angina pec-
toris was deemed present if reported as typical chest pain or,
in patients with uncertain pain, if typical angina occurred
during the stress test. For MPS studies, a defect score
Table 1. Five-Year Baseline Characteristics of the Prognostic Study
Patient Population With Normal as Compared With Abnormal Scintigraphic
Findings
Baseline
Normal MPS
(n ¼ 134)
Abnormal MPS
(n ¼ 205) p Value
Age, yrs 71  9 73  10 0.042
Male 73 88 0.001
Previous MI 10 36 <0.001
Diabetes 16 13 0.53
Hyperlipidemia 81 82 1.00
Hypertension 66 61 0.42
Smoking 22 21 1.00
STEMI* 11 22 0.008
ACS* 32 40 0.11
Chronic CAD* 57 37 0.003
Multivessel disease 52 73 <0.001
BMS use 31 31 1.00
Angina at 5-yr MPS 10 11 0.719
LVEF at 5-yr MPS 63  7 51  11 <0.001
Values are mean  SD or %. *The initial BASKET intervention.
ACS ¼ acute coronary syndromes; BMS ¼ bare metal stent; CAD ¼ coronary artery disease;
LVEF ¼ left ventricular ejection fraction; MPS ¼ myocardial perfusion scintigraphy;
STEMI ¼ ST-segment elevation myocardial infarction.
Figure 1. Patient Flow Chart of the Study Population
The ﬂow chart shows the derivation of the study population from 826
consecutive patients for the clinical follow-up and the repeat scintigraphic
studies. BASKET ¼ Basel Stent Kosten-Effektivitäts Trial; MPS ¼ myocardial
perfusion scintigraphy.
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617that affected 5% myocardium was considered signiﬁcant
(1). Overall abnormality (i.e., reversible defects indicating
ischemia and ﬁxed defects indicating scar) was evaluated.
Defects in the myocardial area of the initially treated ves-
sel(s) were labeled treated-vessel defects and those in other
myocardial regions remote defects.
Analyses. In a ﬁrst step, baseline characteristics of the
present study population were compared with the original
BASKET population; the 33 patients without ﬁnal follow-
up information were evaluated separately. Then the 5-year
baseline characteristics of the prognostic cohort were com-
pared between those with versus without a positive MPS
result. For outcome analyses, the primary and secondary
endpoints were determined with regard to the MPS result.
Then, MACE rates of subgroups of patients with versus
without angina pectoris, those of patients with symptomatic
versus silent ischemia as well as for patients with treated-
vessel versus remote ischemia, respectively, were analyzed.
Statistics. Data are presented as mean  SD or percentages
as appropriate. The groups were compared with the Fisher
exact test for categorical variables and the unpaired Student
t test for numeric variables. Cumulative hazard curves were
used to compare outcomes between patient groups using the
log-rank test. Hazard ratios (HRs)  95% conﬁdence in-
tervals (CIs) were calculated using a Cox regression model.
Cox regression models were also used to identify signiﬁcant
univariate and multivariate predictors of endpoints. All signiﬁ-
cantly different parameters in baseline variables (Table 1: age,
sex, ST-segment elevationMI at baseline, multivessel disease
at baseline, left ventricular ejection fraction [at 5-year MPS],
treated-vessel ischemia, and remote ischemia) were used for
the primary endpoint MACE, and age, LVEF and the
extent of ischemia by MPS (SDS) (all at the 5-year baseline)for the secondary endpoint of cardiac death/MI. A value
of p < 0.05 was considered statistically signiﬁcant. SPSS
software version 21 (IBM Inc., Armonk, New York) was used.
Role of the funding source. The Swiss Heart Foundation
had no role whatsoever in the design, conduct, or interpre-
tation of this study.
Results
Patients and baseline characteristics. The main character-
istics of the present study population with outcome informa-
tion (n ¼ 339) at BASKET baseline (i.e., 5 years before the
start of the present study), are compared with BASKET
patients not participating in the present study in Table 2.
Because the latter contained all 115 patients who died during
these 5 years, the present study population was somewhat
younger and more often male and had less often ST-segment
elevation MI and multivessel disease as presenting problems,
with some additional differences in coronary risk factors. Study
patients were 72 10 years of age, 18%were female, and 90%
were free of angina at the time of the 5-year follow-up MPS.
MPS ﬁndings. Stress was performed by bicycle ergometry
alone in 69% of patients and by pharmacological stress with
adenosine infusion in 31%. A signiﬁcant perfusion defect
(scar or ischemia) was noted in 205 of 339 patients (60%),
defects being ﬁxed (scar) only in 139 patients, reversible
only (ischemia) in 58 patients, and combined ﬁxed and
reversible (scar and ischemia) in 8 patients. Of the reversible
perfusion defects (ischemia), 55% were attributed to the ini-
tially treated vessels, 33% to remote regions, and 12% to both.
Figure 2. Cumulative MACE for Patients With Normal Compared
With Abnormal MPS Findings
Note the higher major cardiac adverse event (MACE) rates at 2 years in
patients with abnormal myocardial perfusion scintigraphy (MPS) ﬁndings after
5 years.
Table 2. Baseline Characteristics (at BASKET Baseline) of the Prognostic
Study Population in Relation to the Total BASKET Population and BASKET
Patients Without 5-Year Follow-up
Baseline
All BASKET
(n ¼ 826)
No 5-Yr
Follow-up
(n ¼ 487)
5-Yr Follow-up
(n ¼ 339) p Value
Age, yrs 64  11 65  12 63  10 0.01
Male 79 76 82 0.05
Previous MI 27 29 26 0.383
Diabetes 19 22 14 0.005
Hyperlipidemia 75 70 82 <0.001
Hypertension 67 68 63 0.155
Smoking 28 33 22 <0.001
STEMI* 21 24 18 0.05
ACS* 36 36 37 0.72
Chronic CAD* 42 40 45 0.21
Multivessel disease 70 71 65 0.051
BMS use 34 36 31 0.136
Values are mean  SD or %. *The initial BASKET intervention.
ACS ¼ acute coronary syndromes; BMS ¼ bare metal stent; CAD ¼ coronary artery disease;
STEMI ¼ ST-segment elevation myocardial infarction.
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618Baseline characteristics of the prognostic patient popula-
tion (n ¼ 339) at the time of the MPS study are compared in
Table 1 in relation to MPS study results. Patients with an
abnormal MPS result were older and more often male and
more often had a previous MI, also ST-segment elevation
MI as a presenting problem 5 years earlier together with a
higher rate of multivessel coronary disease at that point in
time. Thus, scintigraphically determined left ventricular
ejection fraction at the time of the 5-year MPS study was
lower in patients with an abnormal MPS result. However,
the rates of angina at 5 years and at ﬁnal follow-up were
not different (Table 1, Online Table 1). The same held true
for the medications at ﬁnal follow-up (Online Table 1).
Corresponding data for the 33 patients withdrawing
consent or lost to long-term follow-up did not differ from
the total prognostic population except for rates of diabetes
and smoking, and their MPS ﬁndings were not different
from those of patients in the prognostic cohort (Online
Table 2).
Follow-up events in relation to MPS ﬁndings. During a mean
follow-up of 3.7  1.3 years (range, 3.1 to 4.8 years) in the
339 patients with complete follow-up information, 7 cardiac
deaths, 7 noncardiac deaths, 18 documented MIs, and 47
repeat revascularization procedures (38 PCIs, 9 surgeries)
were reported. Overall, 55 patients had at least 1 MACE,
for a cardiac event rate of 4.4% per year of follow-up or a
cardiac mortality rate of 0.6% per year. Patients with
abnormal MPS ﬁndings had a higher cumulative MACE
rate (HR: 1.95; 95% CI: 1.06 to 3.59; p ¼ 0.032), as shown
in Figure 2, as well as a trend to a higher cardiac death/MI
rate (HR: 2.50; 95% CI: 0.93 to 6.69; p ¼ 0.066) thanpatients with normal ﬁndings. The annual cardiac death
rate was not statistically different in patients with versus
without normal MPS ﬁndings (0.2% and 0.8%, respectively,
p ¼ 0.252). Note that normal ﬁndings on MPS predicted an
excellent outcome with a yearly MACE rate of only 3% and
a cardiac mortality rate of 0.2% per year of follow-up. The
only independent predictor of cardiac death/MI was the
extent of ischemia (SDS per point) (HR: 1.16; 95% CI: 1.07
to 1.26; p < 0.001).
Findings in relation to symptomatic or silent ischemia and
localization of ischemia. Any scintigraphic ischemia as
deﬁned for this study was detected in 66 patients (19.5%).
The MACE rate in patients with ischemia was higher than
in those without ischemia (HR: 2.65; 95% CI: 1.51 to 4.65;
p ¼ 0.001). In these 66 patients, ischemia was symptomatic
in 17% and silent in 83% (16% of the total prognostic
patient population). Figure 3 shows that cumulative rates of
MACE were similar in patients with symptomatic (36%)
and silent (27%) ischemia (p ¼ 0.610) but higher than in
patients with normal ﬁndings on MPS (11%) (p < 0.05 for
both). However, the outcome was not inﬂuenced by pres-
ence of scintigraphic scar (16% MACE rate, both in pa-
tients with and without scar). The MACE rate in patients
with treated-vessel ischemia was 19%, not signiﬁcantly
different from that of patients without this ﬁnding (16%;
p ¼ 0.629), whereas the MACE rate of patients with
remote ischemia was higher than that of patients without
remote ischemia (41% vs. 14%, p ¼ 0.003). In the Cox
regression analysis, remote ischemia was the only indepen-
dent predictor of MACE (HR: 4.1; 95% CI: 1.97 to 8.37;
p < 0.001).
Figure 3. Cumulative MACE in Patients With Symptomatic and Silent
Ischemia and in Patients With Normal MPS Findings
Note that MACE rates were higher for patients with symptomatic or silent
ischemia (36% and 27%, respectively, p ¼ 0.455) than for patients with normal
MPS ﬁndings (11%; p < 0.05 for both comparisons). Abbreviations as in
Figure 2.
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619Discussion
These ﬁndings of the BASKET LATE IMAGING study
document a strong prognostic value of routine stress imaging
5 years after successful PCI and stent implantation, irre-
spective of recurrent symptoms. It is the ﬁrst reasonably
sized prospective study evaluating the prognostic value of
routine stress MPS 5 years after PCI in patients selected
neither for symptoms nor for particularly high risk. Impor-
tantly, the outcome of patients with normal MPS ﬁndings
was excellent, but the prevalence of silent ischemia was high
and its predictive power for future events similar to that of
symptomatic ischemia. The observation that there was an
independently predictive value of remote compared with
treated-vessel ischemia 5 years after the intervention in-
dicates that, at this point in time, progression of CAD in
remote vessel areas seems to be more relevant than late
intervention-related treated-vessel problems.
Previous studies on stress imaging after PCI focused on
the early period within the ﬁrst year after the intervention
only or primarily on symptomatic patients (5,17–22). The
results of these studies were controversial, leading to the
recommendation that routine stress testing of asymptomatic
patients <2 years after the intervention should not be per-
formed without speciﬁc indications (23,24). In predicting
future events very late after PCI, one has to consider that at
this point in time, patients are elderly (>70 years of age),
such that mortality was as high for extracardiac as for
cardiac causes in the present study; that patients presented ina stable condition, indicating that overall yearly event rates
are low (4.4% for MACE and 2% for cardiac death/MI
in the present study); and that >90% of patients were
asymptomatic, such that for them, symptoms leading to the
need for (repeat) revascularization was a major event. Note
that new relevant symptoms often reﬂect CAD progression,
which may manifest as new or increasing vessel obstructions
rather than abrupt vessel closures. Only the extent of is-
chemia (SDS) predicted the secondary endpoint of cardiac
death/MI, whereas only remote ischemia independently
predicted follow-up MACE. This suggests that very late
after PCI, progression of CAD becomes prognostically more
important than stent-related problems, a ﬁnding that is
equally important for stent safety assessments as for patients:
it implies the need for continued intense secondary pre-
vention of CAD.
Although the aim of the original BASKET was to
achieve full revascularization in all patients (13), which was
documented after 6 months in 93% of available patients for
follow-up MPS (6), it cannot be veriﬁed that ischemia after
5 years was due to not fully revascularized CAD at BAS-
KET baseline or whether it all was due to progression of
minimal disease or new development of signiﬁcant lesions.
A recent speciﬁc analysis showed that in fact progression or
new development of CAD is relevant late (5 years) after
revascularization (1). However, this differentiation seems
of limited relevance in view of the prognostic importance
of such a test if performed in unselected post-stenting
patients.
The question remains unanswered whether patients with
silent ischemia, as detected at a high rate in the present
study, should be managed by repeat intervention or opti-
mized medical therapy to improve outcomes similar to pa-
tients with symptomatic ischemia. Two small randomized
trials, the ACIP (Asymptomatic Coronary Ischemia Pilot)
study (25) and the SWISSI (Swiss Interventional Study on
Silent Ischemia) II (26) suggested that repeat revasculari-
zation improves prognosis in patients with silent ischemia.
A recent nonrandomized study in 769 asymptomatic pati-
ents with previous revascularization and inducible ischemia
detected by myocardial perfusion imaging questioned this
notion because 15% of patients selected for repeat revascu-
larization had no survival beneﬁt compared with 85% of
patients selected for medical therapy (23). However, this
study was subject to a major selection bias: in patients with a
coronary anatomy already known from an average of 2
previous revascularizations, the clinical decision to perform
another revascularization will rarely depend only on the
presence or absence of myocardial ischemia at follow-up.
Remaining options for revascularization, willingness of pa-
tients to undergo a further intervention despite the absence
of symptoms, comorbidities, and whether these patients
were fully revascularized initially or tested before entering a
rehabilitation program or before noncardiac surgery are just
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620some of the factors that were missed, even with multiple sta-
tistical adjustments to account for treatment group differences.
Another recent observational study in which only 34% of
262 patients with exercise ischemia after revascularization
were selected for repeat revascularization were subject to
similar limitations (23). Both studies and an invited com-
ment on the basis of 2 older studies (27) concluded that pa-
tients at increased risk may be detected, but that they do
not seem to beneﬁt from repeat revascularization such that
routine testing in asymptomatic patients may not be justiﬁed
(24,28). However, only large randomized, controlled trials
will be able to answer the question of how the outcomes of
patients with silent ischemia can be improved, an outcome
that was similar to that of symptomatic ischemia in the
present study years after PCI (22). Perhaps the ongoing
ISCHEMIA (International Study of Comparative Health
Effectiveness with Medical and Invasive Approaches) or the
TIME-DM (Trial of Invasive versus Medical therapy of
Early coronary artery disease in Diabetes Mellitus) will be
able to answer part of this question. A general recommen-
dation to perform a routine ischemia test late after PCI and
stenting would, therefore, only be justiﬁed if a dedicated
treatment trial would show a beneﬁt of treating such patients
with mainly silent ischemia, taking into account a cost-
beneﬁt evaluation. Thus, present ﬁndings do not call for
routine testing in all such patients but highlight the im-
portance of CAD progression 5 years after PCI, often
occurring silently, and its impact on long-term outcome.
Study limitations. Limitations of this noninvasive follow-
up study relate to the fact that coronary angiographic data
were not available in any of these patients at the time of
the 5-year MPS study. Thus, anatomic mechanisms un-
derlying observed perfusion defects remain undeﬁned. This
would be particularly interesting in the treated-vessel area
to differentiate a restenotic process from CAD progression
in the same vessel distant to the treated segment. However,
some patients were not available for the 5-year MPS study,
and some could not be located for the ﬁnal follow-up,
almost 9 years after the BASKET intervention. Still, the
rate of patients available for these investigations was
remarkably high (91%) and only possible in a stationary
population as typical for our region. In addition, the com-
parison of baseline data documented that the present study
population was fairly representative of what could be ex-
pected 5 years after an intervention. Note, however, that
secondary prevention was not optimal, although the rate of
antiplatelet, statin, and beta-blocker drugs was high (>70%
to 90%) for mostly asymptomatic patients in an observa-
tional long-term trial. Finally, we cannot extrapolate from
these results whether similar ﬁndings could have been
found 2, 3, or 4 years after PCI already or whether ﬁndings
would have been similar in 1-vessel PCI patients. The
observation that 5 years after the intervention the prog-
nostic value of treated-vessel ischemia was lower than thatof remote ischemia indicates that the reason for late cardiac
stress imaging may be the detection of persistent or pro-
gressive CAD rather than very late intervention-related
problems.
Conclusions
BASKET LATE IMAGING documents the prognostic
value of routine cardiac stress imaging 5 years after successful
PCI and stent implantation irrespective of recurrent symp-
toms. Its predictive power lies more in the detection of
persistent or progressive CAD in remote-vessel areas than
in the diagnosis of very late intervention-related problems
in the treated vessels. Findings emphasize the importance
of long-term secondary prevention of CAD and call for a
randomized, controlled trial to deﬁne the optimal manage-
ment of patients with ischemia very late after revascu-
larization, irrespective of symptoms, and its cost-beneﬁt
implications.
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